Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anna Bacco"'
Autor:
Annalisa Sechi, Lucrezia Zuccarelli, Bruno Grassi, Rita Frangiamore, Ramona De Amicis, Mauro Marzorati, Simone Porcelli, Annarita Tullio, Anna Bacco, Simona Bertoli, Andrea Dardis, Lea Biasutti, Maria Barbara Pasanisi, Grazia Devigili, Bruno Bembi
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-11 (2020)
Abstract Background Late onset Pompe disease (LOPD) is a lysosomal neuromuscular disorder which can progressively impair the patients’ exercise tolerance, motor and respiratory functions, and quality of life. The available enzyme replacement therap
Externí odkaz:
https://doaj.org/article/ee6bce0c704144d6b69bc06dbc26f16c
Autor:
Debora Basile, Annamaria Parnofiello, Maria Grazia Vitale, Francesco Cortiula, Lorenzo Gerratana, Valentina Fanotto, Camilla Lisanti, Giacomo Pelizzari, Elena Ongaro, Michele Bartoletti, Silvio Ken Garattini, Victoria Josephine Andreotti, Anna Bacco, Donatella Iacono, Marta Bonotto, Mariaelena Casagrande, Paola Ermacora, Fabio Puglisi, Nicoletta Pella, Gianpiero Fasola, Giuseppe Aprile, Giovanni G. Cardellino
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 2, Pp 368-377 (2019)
Abstract Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impair
Externí odkaz:
https://doaj.org/article/a2790e6e4fbc47f6b1da3b2ceecde791
Autor:
Simona Bertoli, Bruno Grassi, Grazia Devigili, Maria Barbara Pasanisi, Anna Bacco, Lea Biasutti, Mauro Marzorati, Lucrezia Zuccarelli, Bruno Bembi, Ramona De Amicis, Annarita Tullio, Andrea Dardis, Simone Porcelli, Rita Frangiamore, Annalisa Sechi
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-11 (2020)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases
Background Late onset Pompe disease (LOPD) is a lysosomal neuromuscular disorder which can progressively impair the patients’ exercise tolerance, motor and respiratory functions, and quality of life. The available enzyme replacement therapy (ERT) d
Autor:
Michele Bartoletti, Gianpiero Fasola, Fabio Puglisi, Giuseppe Aprile, Anna Bacco, Lorenzo Gerratana, Silvio Ken Garattini, Valentina Fanotto, Nicoletta Pella, Maria Grazia Vitale, A. Parnofiello, Elena Ongaro, Paola Ermacora, Debora Basile, V.J. Andreotti, F. Cortiula, Mariaelena Casagrande, Giacomo Pelizzari, C. Lisanti, Marta Bonotto, Giovanni Gerardo Cardellino, Donatella Iacono
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 2, Pp 368-377 (2019)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle
Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impaired qualit